BioMarin's Pompe Disease Therapy Shows Five-Year Durability in Phase 3 Data
Event summary
- BioMarin presented five-year Phase 3 data for POMBILITI + OPFOLDA in late-onset Pompe disease at the World Muscle Society Annual Congress.
- 82 patients showed durable motor function and pulmonary stabilization, with 62 ERT-experienced and 20 ERT-naïve participants.
- Mean change in six-minute walk distance was 0.7% for ERT-experienced and 10.5% for ERT-naïve patients over five years.
- No new safety signals identified, though 51.2% of participants experienced manageable treatment-related adverse events.
The big picture
BioMarin's five-year data for POMBILITI + OPFOLDA reinforces its position in the rare disease space, particularly in late-onset Pompe disease where long-term therapy options are limited. The durable efficacy and safety profile could strengthen its competitive edge against existing enzyme replacement therapies. Meanwhile, positive early data for nivudirsen in Duchenne muscular dystrophy suggests BioMarin is expanding its pipeline beyond Pompe disease, targeting another high-need neuromuscular indication.
What we're watching
- Therapeutic Durability
- Whether POMBILITI + OPFOLDA can maintain long-term efficacy in a broader late-onset Pompe disease population beyond the study cohort.
- Regulatory Pathway
- The pace at which BioMarin advances POMBILITI + OPFOLDA through regulatory approvals for expanded use in LOPD patients.
- Pipeline Progress
- How Phase 1/2 data for nivudirsen (BMN 351) in Duchenne muscular dystrophy will impact BioMarin's rare disease portfolio diversification.
Related topics